Park Place Capital Corp Sells 81 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Park Place Capital Corp reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.1% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,886 shares of the medical equipment provider’s stock after selling 81 shares during the period. Park Place Capital Corp’s holdings in Intuitive Surgical were worth $753,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Norges Bank bought a new stake in Intuitive Surgical in the fourth quarter worth about $1,313,238,000. WCM Investment Management LLC purchased a new stake in shares of Intuitive Surgical in the fourth quarter worth approximately $575,536,000. International Assets Investment Management LLC lifted its stake in shares of Intuitive Surgical by 32,360.5% during the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after acquiring an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd boosted its holdings in Intuitive Surgical by 113.2% during the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after acquiring an additional 677,455 shares during the period. Finally, Coatue Management LLC grew its position in Intuitive Surgical by 65.7% in the 4th quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after acquiring an additional 516,054 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

NASDAQ:ISRG traded down $8.61 during midday trading on Monday, reaching $436.24. 1,657,860 shares of the stock traded hands, compared to its average volume of 1,528,116. The stock has a market capitalization of $154.73 billion, a PE ratio of 78.96, a price-to-earnings-growth ratio of 5.75 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $448.10. The business has a 50-day moving average of $403.83 and a two-hundred day moving average of $383.50.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the business posted $1.00 EPS. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. Research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mark J. Rubash sold 1,709 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $380.00, for a total value of $649,420.00. Following the completion of the transaction, the director now owns 16,051 shares of the company’s stock, valued at $6,099,380. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,956 shares of company stock valued at $6,927,011. 0.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ISRG has been the subject of several research analyst reports. Robert W. Baird decreased their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. BTIG Research boosted their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Piper Sandler raised their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Jefferies Financial Group lifted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Finally, The Goldman Sachs Group initiated coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $403.67.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.